- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02551874
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
November 20, 2018 updated by: AstraZeneca
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
CV181-369; A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy
Study Type
Interventional
Enrollment (Actual)
650
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Karlovy Vary, Czechia, 360 01
- Research Site
-
Olomouc, Czechia, 772 00
- Research Site
-
-
-
-
-
Koebenhavn, Denmark, 2400
- Research Site
-
-
-
-
-
Budapest, Hungary, 1171
- Research Site
-
Budapest, Hungary, 1097
- Research Site
-
Budapest, Hungary, 1032
- Research Site
-
-
-
-
-
Guadalajara, Mexico, 44670
- Research Site
-
Mexico, Mexico, 03800
- Research Site
-
Monterrey, Mexico, 64460
- Research Site
-
Zapopan, Jalisco, Mexico, 45200
- Research Site
-
-
-
-
-
Lodz, Poland, 92-003
- Research Site
-
Nowy Duninow, Poland, 09-505
- Research Site
-
Sochaczew, Poland, 96-500
- Research Site
-
-
-
-
-
Craiova, Romania, 200349
- Research Site
-
Ploiesti, Romania, 100018
- Research Site
-
Timisoara, Romania, 300125
- Research Site
-
Timișoara, Romania, 300456
- Research Site
-
-
-
-
-
Lenasia, South Africa, 1827
- Research Site
-
-
-
-
-
La Coruña, Spain, 15006
- Research Site
-
-
-
-
-
Uddevalla, Sweden, 451 80
- Research Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Research Site
-
Los Angeles, California, United States, 90057
- Research Site
-
-
Florida
-
Miami, Florida, United States, 33144
- Research Site
-
Miami, Florida, United States, 33155
- Research Site
-
Saint Petersburg, Florida, United States, 33709
- Research Site
-
-
Georgia
-
Norcross, Georgia, United States, 30071
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40502
- Research Site
-
-
Massachusetts
-
Quincy, Massachusetts, United States, 02169
- Research Site
-
-
Ohio
-
Beavercreek, Ohio, United States, 45432
- Research Site
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
- Research Site
-
-
Pennsylvania
-
Barto, Pennsylvania, United States, 19504
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
- Research Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Research Site
-
Kingsport, Tennessee, United States, 37660
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77004
- Research Site
-
Mesquite, Texas, United States, 74194
- Research Site
-
San Antonio, Texas, United States, 78258
- Research Site
-
San Antonio, Texas, United States, 78230
- Research Site
-
-
Utah
-
Bountiful, Utah, United States, 84010
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 120 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- At least 18 years of age at screening
- HbA1c ≥ 8% and ≤ 12% at screening
- Fasting plasma glucose (FPG) ≤ 270 mg/dL (15mmol/L)
- Stable dose metformin ≥ 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks
- estimated glomerular filtration rate (eGFR) < 60 ml/ml/1.73m2
- Body Mass Index ≤ 45.0 kg/m2
Exclusion Criteria:
- Clinical diagnosis of Type 1 diabetes
- History of ketoacidosis
- Renal, hepatic or pancreatic disease
- Impairment of renal function (defined as creatinine clearance [CrCl] < 60 mL/min
- Cardiovascular or vascular diseases identified within 3 months of participationImpairment of renal function (defined as creatinine clearance [CrCl] < 60 mL/min
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Saxagliptin/Dapagliflozin/Metformin
Oral route.
Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
|
Tablets, Oral, 5mg , Once daily, 24 weeks
Other Names:
Tablets, Oral, 10mg , Once daily, 24 weeks
Other Names:
Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
Other Names:
|
Active Comparator: Insulin Glargine, Lantos/Metformin
Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
|
100 Units/ml solution for injection in a prefilled SoloStar pen
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in HbA1c at Week 24
Time Frame: Baseline and Week 24
|
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
|
Baseline and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Total Body Weight at Week 24
Time Frame: Baseline and Week 24
|
To compare the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment
|
Baseline and Week 24
|
Percentage of Subjects With Confirmed Hypoglycaemia at Week 24
Time Frame: Baseline and Week 24
|
Hypoglycemia defined as plasma glucose ≤70 mg/dL (3.9 mmol/L)
|
Baseline and Week 24
|
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24
Time Frame: Baseline and Week 24
|
To compare the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c <7.0%, without any reported hypoglycemia, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU versus titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
|
Baseline and Week 24
|
Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24
Time Frame: Baseline and Week 24
|
To examine whether the percentage of subjects achieving a therapeutic glycemic response, defined as HbA1c <7.0%, with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 10%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
|
Baseline and Week 24
|
Change From Baseline in the Mean Value of 24-hour Glucose at Week 2
Time Frame: Baseline and Week 2
|
Change from baseline in the mean value of 24-hour glucose readings measured by Continuous Glucose Monitoring with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior to titrated insulin glargine plus metformin with or without SU after 2 weeks of open-label treatment.
|
Baseline and Week 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: AstraZeneca, AstraZeneca
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2015
Primary Completion (Actual)
May 8, 2017
Study Completion (Actual)
November 10, 2017
Study Registration Dates
First Submitted
September 15, 2015
First Submitted That Met QC Criteria
September 15, 2015
First Posted (Estimate)
September 16, 2015
Study Record Updates
Last Update Posted (Actual)
December 11, 2018
Last Update Submitted That Met QC Criteria
November 20, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Sodium-Glucose Transporter 2 Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Dapagliflozin
- Metformin
- Insulin Glargine
- Saxagliptin
Other Study ID Numbers
- CV181-369
- 2015-001702-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Saxagliptin, Onglyza
-
AstraZenecaCompletedType 2 Diabetes MellitusBrazil
-
AstraZenecaWithdrawn
-
AstraZenecaCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaCompleted
-
AstraZenecaCompletedBioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and MetforminUnited States
-
AstraZenecaCompleted
-
Beni-Suef UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Unity Health TorontoCompletedHeart Failure | Diabetes Mellitus, Non-Insulin-DependentCanada